Gene Logic Inc. has agreed to share its quality-control methods and metrics with the FDA to help the agency better understand disparate genomic data submitted as part of approval applications. (BioWorld Today)

Four months after licensing a preclinical, second-generation antisense drug for high cholesterol to Bristol-Myers Squibb Co. in a deal worth up to $192 million, Isis Pharmaceuticals Inc. is at it again. (BioWorld Today)